2024-06-20 03:14:50 ET
Summary
- Compass Therapeutics is an oncology-focused biotech developing novel immunotherapies for solid tumors, with a focus on gastrointestinal cancers.
- Their most advanced candidate, CTX-009, targets DLL4 and VEGF in biliary tract cancer, showing promising early response rates.
- Despite financial stability and potential game-changing catalysts, risks include toxicity concerns and comparator arm issues in their phase 3 trial.
Topline Summary
Read the full article on Seeking Alpha
For further details see:
Compass Therapeutics: Pointing Right At Some Tough Cancers